Pharminent

Novartis licenses CAR-T patents from Celyad

Celyad has granted Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents. http://contractservices.pharmaceutical-business-review.com/news/celyad-grants-non-exclusive-license-for-allogeneic-tcr-deficient-car-t-cells-patents-to-novartis-030517-5803243

Filed under: Cancer, Immunotherapy